Literature DB >> 19359255

Comorbidities in pediatric epilepsy: beyond "just'' treating the seizures.

L D Hamiwka1, E C Wirrell.   

Abstract

The goal of this review is to discuss the comorbidities reported in specific epilepsy syndromes to examine possible underlying causes or associations and to present data on current therapies for these conditions. Comorbid conditions including cognitive impairment, neuropsychiatric problems, and social difficulties are common in children with epilepsy, and often more disabling than the seizures themselves. Biological factors associated with a greater risk of comorbidity in epilepsy include younger age at seizure onset, cognitive impairment, temporal or frontal lobe onset, and intractability. Social factors correlating with greater risk include lower socioeconomic status, lower parental education level, and poorer family function. These comorbid conditions not only have a significant impact on the child but also are a source of increased stress and burden for families. Increased awareness and early diagnosis of these conditions may affect therapeutic intervention and long-term outcome as well as assist in better understanding of potential risk factors and biological mechanisms.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19359255     DOI: 10.1177/0883073808329527

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  21 in total

1.  Treatment factors affecting longitudinal quality of life in new onset pediatric epilepsy.

Authors:  Avani C Modi; Lisa M Ingerski; Joseph R Rausch; Tracy A Glauser
Journal:  J Pediatr Psychol       Date:  2011-01-29

2.  Issues in Clinical Epileptology: A View from the Bench. A Festschrift in Honor of Philip A. Schwartzkroin, PhD.

Authors:  Carl E Stafstrom
Journal:  Epilepsy Curr       Date:  2013-11       Impact factor: 7.500

3.  Cognitive Outcome in Childhood-Onset Epilepsy: A Five-Decade Prospective Cohort Study.

Authors:  Mira Karrasch; Petri Tiitta; Bruce Hermann; Juho Joutsa; Shlomo Shinnar; Juha Rinne; Anu Anttinen; Matti Sillanpää
Journal:  J Int Neuropsychol Soc       Date:  2017-01-10       Impact factor: 2.892

Review 4.  Quantifying the deficit-imaging neurobehavioural impairment in childhood epilepsy.

Authors:  Michael Yoong
Journal:  Quant Imaging Med Surg       Date:  2015-04

5.  Children with epilepsy demonstrate macro- and microstructural changes in the thalamus, putamen, and amygdala.

Authors:  Sarah J MacEachern; Jonathan D Santoro; Kara J Hahn; Zachary A Medress; Ximena Stecher; Matthew D Li; Jin S Hahn; Kristen W Yeom; Nils D Forkert
Journal:  Neuroradiology       Date:  2019-12-18       Impact factor: 2.804

6.  Impaired cognition in rats with cortical dysplasia: additional impact of early-life seizures.

Authors:  Marcella M Lucas; Pierre-Pascal Lenck-Santini; Gregory L Holmes; Rod C Scott
Journal:  Brain       Date:  2011-05-20       Impact factor: 13.501

7.  Conditional Loss of Arx From the Developing Dorsal Telencephalon Results in Behavioral Phenotypes Resembling Mild Human ARX Mutations.

Authors:  Jacqueline C Simonet; C Nicole Sunnen; Jue Wu; Jeffrey A Golden; Eric D Marsh
Journal:  Cereb Cortex       Date:  2014-05-02       Impact factor: 5.357

8.  Pretreatment neuropsychological deficits in children with brain tumors.

Authors:  L Iuvone; L Peruzzi; C Colosimo; G Tamburrini; M Caldarelli; C Di Rocco; D Battaglia; F Guzzetta; S Misciagna; A Di Giannatale; A Ruggiero; R Riccardi
Journal:  Neuro Oncol       Date:  2011-03-03       Impact factor: 12.300

9.  Epilepsy among children and adolescents with autism spectrum disorders: a population-based study.

Authors:  Elina Jokiranta; Andre Sourander; Auli Suominen; Laura Timonen-Soivio; Alan S Brown; Matti Sillanpää
Journal:  J Autism Dev Disord       Date:  2014-10

10.  Predictors of trajectories of epilepsy-specific quality of life among children newly diagnosed with epilepsy.

Authors:  Rachelle R Ramsey; Kristin Loiselle; Joseph R Rausch; Jordan Harrison; Avani C Modi
Journal:  Epilepsy Behav       Date:  2016-03-12       Impact factor: 2.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.